Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Updates to the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) 2021 include recommendations biomarker testing in all appropriate patients with newly diagnosed advanced lung cancer, including squamous cell cancer. When a targetable genetic alteration is detected, recommend treatment first-line therapy targeted that alteration. The guidelines contain new information on use of adjuvant osimertinib resected early-stage EGFR -mutated NSCLC. New agents are now recommended ALK rearrangements, RET alterations, MET exon 14 skipping mutations NSCLC; and immunotherapy NSCLC without driver oncogene.